Literature DB >> 12637154

A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines.

Eric E Williams1, Laurie J Trout, Richard M Gallo, Sarah E Pitfield, Ianthe Bryant, Desi J Penington, David J Riese.   

Abstract

ErbB4 (HER4) is a member of the ErbB family of receptor tyrosine kinases, a family that also includes the Epidermal Growth Factor Receptor (EGFR/ErbB1/HER1), Neu/ErbB2/HER2, and ErbB3/HER3. Several groups have hypothesized that signal transduction by the ErbB4 receptor tyrosine kinase is coupled to differentiation, growth arrest, and tumor suppression in mammary and prostate epithelial cells. In this report we demonstrate that a constitutively active ErbB4 mutant inhibits the formation of drug-resistant colonies by the DU-145 and PC-3 human prostate tumor cell lines. This is consistent with our hypothesis that ErbB4 signaling is growth inhibitory and may be coupled to tumor suppression in prostate cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12637154     DOI: 10.1016/s0304-3835(02)00690-0

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  19 in total

1.  Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.

Authors:  Richard M Gallo; Ianthe Bryant; Rachael Fry; Eric E Williams; David J Riese
Journal:  Biochem Biophys Res Commun       Date:  2006-08-18       Impact factor: 3.575

2.  The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056.

Authors:  Richard M Gallo; David J Riese
Journal:  Growth Factors       Date:  2007-10       Impact factor: 2.511

3.  Druggability and Binding Site Interaction Studies of Potential Metabolites Isolated from Marine Sponge Aurora globostellata against Human Epidermal Growth Factor Receptor-2.

Authors:  M Sugappriya; D Sudarsanam; Raj Bhaskaran; Jerrine Joseph; Arumugam Suresh
Journal:  Bioinformation       Date:  2017-08-31

4.  ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.

Authors:  Christopher P Mill; Michael D Zordan; S Michael Rothenberg; Jeffrey Settleman; James F Leary; David J Riese
Journal:  Genes Cancer       Date:  2011-08

5.  Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

Authors:  Maitreyee K Jathal; Liqun Chen; Maria Mudryj; Paramita M Ghosh
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2011-06

6.  Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.

Authors:  Christopher P Mill; Kathleen L Gettinger; David J Riese
Journal:  Exp Cell Res       Date:  2010-11-24       Impact factor: 3.905

7.  A growing family: adding mutated Erbb4 as a novel cancer target.

Authors:  Udo Rudloff; Yardena Samuels
Journal:  Cell Cycle       Date:  2010-04-15       Impact factor: 4.534

Review 8.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

Review 9.  Functional selectivity of EGF family peptide growth factors: implications for cancer.

Authors:  Kristy J Wilson; Jennifer L Gilmore; John Foley; Mark A Lemmon; David J Riese
Journal:  Pharmacol Ther       Date:  2008-12-16       Impact factor: 12.310

10.  Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone.

Authors:  Jennifer L Gilmore; Ryan M Gonterman; Keshav Menon; Gwendolen Lorch; David J Riese; Alex Robling; John Foley
Journal:  Mol Cancer Res       Date:  2009-10-13       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.